Eton Pharmaceuticals Ownership
| ETON Stock | USD 12.03 0.80 7.12% |
Shares in Circulation | First Issued 2017-09-30 | Previous Quarter 25.8 M | Current Value 26.6 M | Avarage Shares Outstanding 20.5 M | Quarterly Volatility 7.3 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Eton |
Eton Stock Ownership Analysis
About 33.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 0.26. Eton Pharmaceuticals had not issued any dividends in recent years. Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois. Eton Pharmaceutcials operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 17 people. To learn more about Eton Pharmaceuticals call Sean Brynjelsen at 847 787 7361 or check out https://www.etonpharma.com.Besides selling stocks to institutional investors, Eton Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Eton Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Eton Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Eton Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Eton Pharmaceuticals Insider Trades History
About 5.0% of Eton Pharmaceuticals are currently held by insiders. Unlike Eton Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Eton Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Eton Pharmaceuticals' insider trades
Eton Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Eton Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Eton Pharmaceuticals backward and forwards among themselves. Eton Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Eton Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Wasatch Advisors Lp | 2024-09-30 | 238.6 K | Aristides Capital Llc | 2024-09-30 | 200 K | Susquehanna International Group, Llp | 2024-06-30 | 134.3 K | Eam Investors, Llc | 2024-09-30 | 128.3 K | Thompson, Siegel & Walmsley Llc | 2024-09-30 | 115 K | Stonepine Capital Management Llc | 2024-06-30 | 110 K | Renaissance Technologies Corp | 2024-09-30 | 83.4 K | State Street Corp | 2024-06-30 | 81.4 K | Bank Of New York Mellon Corp | 2024-06-30 | 74.5 K | Opaleye Management Inc | 2024-09-30 | 2.8 M | Vanguard Group Inc | 2024-09-30 | 1 M |
Eton Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Eton Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Eton Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Eton Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Eton Pharmaceuticals Outstanding Bonds
Eton Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Eton Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Eton bonds can be classified according to their maturity, which is the date when Eton Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View |
Eton Pharmaceuticals Corporate Filings
8K | 25th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 25th of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 12th of September 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
8K | 2nd of August 2024 An amendment to a previously filed Form 8-K | ViewVerify |
Pair Trading with Eton Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eton Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eton Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Eton Stock
| 0.93 | GMAB | Genmab AS | PairCorr |
| 0.92 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.9 | VALN | Valneva SE ADR | PairCorr |
| 0.86 | ME | 23Andme Holding | PairCorr |
| 0.85 | LEGN | Legend Biotech Corp | PairCorr |
The ability to find closely correlated positions to Eton Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eton Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eton Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eton Pharmaceuticals to buy it.
The correlation of Eton Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eton Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eton Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eton Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eton Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in Eton Stock, please use our How to Invest in Eton Pharmaceuticals guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eton Pharmaceuticals. If investors know Eton will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eton Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.13) | Earnings Share (0.26) | Revenue Per Share 1.219 | Quarterly Revenue Growth (0.24) | Return On Assets (0.12) |
The market value of Eton Pharmaceuticals is measured differently than its book value, which is the value of Eton that is recorded on the company's balance sheet. Investors also form their own opinion of Eton Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eton Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eton Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eton Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eton Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eton Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eton Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.